Slides
Page 1
H.C. Wainwright 28th Annual Global Investment Conference September 15, 2026 1
Page 2
Please visit www.VEPPANU.com for Full Prescribing Information. Please visit www.TAVALISSE.com for Full Prescribing Information. Please visit www.REZLIDHIA.com for Full Prescribing Information, including Boxed WARNING. Please visit www.GAVRETO.com for Full Prescribing Information, including Boxed WARNING. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, expected commercial launches and commercial availability, commercial, financial and clinical results, projections of financial perform ance and outlook for 2026, expectations for growing our commercial business and successfully executing our commercial strategy, continued enrollment of our R289 study, presentation of study data, expectation of clinical outcomes, continued ability to develop and commercialize VEPPANU, TAVALISSE, GAVRETO, REZLIDHIA and R289 domestically and in certain in ternational markets, the Company's ability to fund its existing and future clinical development programs, and expectations for our partnering, licensing, commercialization and collaboration efforts. Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward -looking statements and as such are intended to be covered by the safe harbor for “forward-looking statements” provided by the PSLRA. Forward-looking statements can be identified by words such as “plan”, “potential”, “may”, “outlook”, “anticipates”, “expects”, “will”, “promising” and similar expressions in reference to future periods. Forward -looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel’s current beliefs, expectations, and assumptions and hence they inherently invo lve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of Rigel’s control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward -looking statements as a result of these risks and uncertainties, which include, without limitation, anticipated financial performance and profitability for 2026; expected product sales and commercial growth; the anticipated t iming, progress and results of clinical development activities for R289, including enrollment, dose selection and data readouts; the Company's ability to fund its existing and f uture clinical development programs; the commercial launch and commercialization of VEPPANU, including expectations regarding its market opportunity, physician adoption, commercial per formance and potential contribution to Rigel’s commercial portfolio; the Company's ability to successfully execute its commercial strategy; and its partnering, licensing, comm ercialization, collaboration and potential business development activities. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements a s a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of VEPPANU, TAVALISSE, GAVRETO and REZLIDHIA, including uncertainties relating to physician adoption, patient demand, market acceptance, reimbursement and pricing; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding VEPPANU, TAVALISSE, GAVRETO, REZLIDHIA or R289; operational, regulatory or other risks that can affect the timing of enrollment and data availability for R289 clinical development; risks that clinical trials may not be predictive of real- world results or of results in subsequent clinical trials; risks that VEPPANU, TAVALISSE, GAVRETO, REZLIDHIA or R289 may have unintended side effects, adverse reactions or incidents of misuse; the availability of resources to develop or market Rigel’s product candidates; market competition; product demand variability; pricing/reimbursement dynamics; unanticipated business needs and other develo pments, including potential partnering, licensing or other collaboration arrangements, which could impact Rigel's funding needs or other internal resourc e demands, as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and subsequent filings . Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law. Forward-Looking Statements 2